H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sensorion SAS (RFM – Research Report) today and set a price target of €3.00.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily centered around the promising developments in Sensorion’s gene therapy initiatives. The recent data from Regeneron’s DB-OTO study, which showed significant auditory improvements in pediatric patients, serves as a positive indicator for Sensorion’s SENS-501. The study results suggest a durable benefit in treating hearing loss, which aligns with Sensorion’s strategic focus and differentiates it from competitors in the gene therapy space.
Moreover, Sensorion’s approach, particularly its study design that excludes patients with a history of cochlear implants, is seen as a potential advantage. This distinction could lead to clearer interpretations of the therapy’s efficacy. The ongoing progress in Sensorion’s Phase 1/2 Audiogene study, with recruitment for the second cohort underway, further supports the optimism. The early promising data from the first cohort and the anticipated updates in the first half of 2025 reinforce the belief in the company’s potential success in the competitive hearing loss treatment market.